http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-1445193-C
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_49e6d8f504fee44e8bb05bafe0e8eab3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c5ff5c641974f9657c1c7da20d6a8377 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-28 |
| filingDate | 1987-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1996-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6ca1b4aa6fd15853b631ec6f7c4cadb0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3cbf72970d7ac40f174fd6374b8a8ba5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e969bcbab71665fb12b8ad152cf3bab0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7581bea1f1cd5dabde354255d4be277 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_03779453aebc437cb67ef9886d8234a9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90ba42223376d1f8bcaea84714d1b679 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2fe68ff3077be7f3a2ecdd907fdc81d8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5dccfe613e92dc28e8378e505e3d617a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_02541b6dd024a2cb1782d8b7d07d84ba http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ec14eb6a146af993827ea37978d31f3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c405e2476f017210546433eb71e2fd78 |
| publicationDate | 1996-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-1445193-C |
| titleOfInvention | Recombinant plasmid dna pga 23 |
| abstract | FIELD: genetic engineering, biotechnology. SUBSTANCE: method involves the use of new recombinant plasmid pTNF311311Δ, encoding constitutive synthesis of human tumor necrosis factor (HTNF), the strain E. coli SG 20050/pTNF311311Δ, providing the high level of mutant HTNF biosynthesis and recombinant plasmid DNA pGA23 which is an intermediate product for preparing recombinant plasmid pTNF31Δ,. Recombinant plasmid pGA23 consistis of PstI/Bam HI DNA-fragment of plasmid vector pDSI Δ, (3.06 thousand base pairs) containing the genes of dihydrofolate reductase, chloramphenicol acetyltransferase, part Δ.-lactamase gene and terminator of phage T ° 2+ transcription, PstI/Bam HI DNA-fragment of plasmid pLZ 56 containing promoters A2 and A3 of bacteriophage T7 early region and part of β-lactamase gene. Recombinant plasmid pTNF11l, encodes polypeptide 5-157 HTNF and consists of PstI/KpnI DNA-fragment of plasmid pGA23 (1.83 thousand base pairs) containing tandem of strong promotors A2 and A3 of bacteriophage T7 and part of β-lactamase gene, and KpnI/PstI DNA-fragment of plasmid pTNF31D containing semisynthetic artificial gene encoding polypeptide 5-157 HTNF, terminator of phage b transcription and part of D,-lactamase gene (2.79 thousand base pairs). Strain E. coli SG 20050 containing plasmid pTNFλ provides the level of polypeptide expression at HTNF activity 1.25 x b U/ml cell suspension. EFFECT: increased biosynthesis of polypeptide HTNF, simplified technology. |
| priorityDate | 1987-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 245.